ASX Announcements

For a full list of company announcements visit the ASX website.
30 November 2021 Results of Annual General Meeting
30 November 2021 Annual General Meeting Presentation
30 November 2021 Letter to Shareholders
29 November 2021 ResApp receives regulatory approvals for cough counter
23 November 2021 ResApp completes COVID-19 study recruitment in India
19 November 2021 Publication on challenges of diagnosing respiratory disease
18 November 2021 ResApp secures contract with global pharmaceutical company
16 November 2021 Partnership with Carepath for in-home COPD monitoring
15 November 2021 IRB approval for US COVID-19 study modification
9 November 2021 Jobkeeper Payments Notice
28 October 2021 Quarterly Activities Report and Appendix 4C
27 October 2021 Quarterly Results and Investor Conference Call Notification
26 October 2021 Notice of Annual General Meeting
26 October 2021 Presentations at Conferences
26 October 2021 COVID-19 Clinical Studies Update
12 October 2021 Notice under ASX Listing Rule 3.13.1
11 October 2021 ResApp announces FDA 510(k) submission for SleepCheckRx
1 October 2021 Notification regarding unquoted securities - RAP
1 October 2021 Notification of cessation of securities - RAP
1 October 2021 Change of Share Registry
20 September 2021 First patients recruited in COVID-19 clinical study in India
14 September 2021 ResApp receives Advanced and Overseas R&D Finding
1 September 2021 ResAppDx receives regulatory approval in Indonesia
27 August 2021 Appendix 4G
27 August 2021 Corporate Governance Statement
27 August 2021 Appendix 4E and Annual Report
18 August 2021 Investor Webinar Presentation
9 August 2021 ResApp expands COVID-19 clinical program
4 August 2021 Alodokter to launch ResAppDx in Indonesia
4 August 2021 Medgate enters licence agreement with ResApp Health
2 August 2021 Trading halt
30 July 2021 Quarterly Activities Report and Appendix 4C
28 July 2021 Quarterly Results and Investor Conference Call Notification
5 July 2021 Commercial agreement with Doctors on Demand in Australia
5 July 2021 ResApp study data published in peer-reviewed journal
2 July 2021 Notification of cessation of securities - RAP
23 June 2021 ResApp to present at the Gold Coast Investment Showcase
3 June 2021 Medgate extends European ResAppDx trial
20 May 2021 Corporate Overview Presentation
18 May 2021 Initial Director's Interest Notice
18 May 2021 Brian Leedman Reappointed as Executive Director
17 May 2021 First participant recruited in COVID-19 cough study
4 May 2021 Agreement with Ilara Health to sell ResAppDx in Kenya
30 April 2021 Quarterly Activities Report and Appendix 4C
29 April 2021 Quarterly Results and Investor Conference Call Notification
21 April 2021 Change in substantial holding
20 April 2021 Ceasing to be a substantial holder
19 April 2021 Appendix 3G
19 April 2021 Section 708A Notice and Appendix 2A
12 April 2021 Proposed issue of Securities
12 April 2021 ResApp secures firm commitments to raise $5.5 million
8 April 2021 Trading Halt
1 April 2021 Appendix 3G
25 March 2021 TGA clearance achieved for wearable
16 March 2021 Change of Director's Interest Notice - Chris Ntoumenopoulos
16 March 2021 Change of Director's Interest Notice - Tony Keating
16 March 2021 Change of Director's Interest Notice - Roger Aston
16 March 2021 Change in substantial holding
12 March 2021 S&P DJI Announces March 2021 Quarterly Rebalance
12 March 2021 Section 708A Notice and Appendix 2A
12 March 2021 ResApp grants SDK licence to AstraZeneca for asthma program
11 March 2021 Clinical study to develop COVID-19 screening test
4 March 2021 Medgate commences European ResAppDx trial
2 March 2021 Proposed issue of Securities - RAP
2 March 2021 CE Mark achieved for wearable device
26 February 2021 Update on Licencing Agreement with WMA
25 February 2021 Resignation of Joint Company Secretary
24 February 2021 Appendix 4D and Half Year Financial Report
10 February 2021 Pre-Submission package lodged with the US FDA
4 February 2021 ResApp receives $801,738 R&D tax incentive refund and grant
2 February 2021 ResApp strengthens patent position in Europe
29 January 2021 Quarterly Activities Report and Appendix 4C
28 January 2021 Quarterly Results and Investor Conference Call Notification
12 January 2021 Appendix 3G
11 January 2021 ResApp appoints VP, Commercial to progress growth strategy
29 December 2020 SleepCheck Launched on Select Android Devices
23 December 2020 ResApp Terminates MOU with RB
22 December 2020 Software updates for ResAppDx to underpin growth
11 December 2020 S&P DJI Announces December 2020 Quarterly Rebalance
4 December 2020 Appointment of Joint Company Secretary
2 December 2020 Change of Director's Interest Notice
2 December 2020 Appendix 3G
26 November 2020 Notification of Change of Auditor
26 November 2020 Adoption of New Constitution
26 November 2020 Results of Annual General Meeting
26 November 2020 Annual General Meeting Presentation
26 November 2020 2020 Letter to Shareholders
24 November 2020 Positive engagement with US FDA following SleepCheck Pre-Sub
19 November 2020 ResAppDx to be integrated into WMA telehealth application
9 November 2020 Medgate to pilot ResAppDx for telehealth across Europe
30 October 2020 Quarterly Activities Report and Appendix 4C
28 October 2020 ResAppDx launched on select Android devices
27 October 2020 Quarterly Results and Investor Conference Call Notification
26 October 2020 Notice of Annual General Meeting/Proxy Form
22 October 2020 AstraZeneca to use new ResApp software in clinical study
21 October 2020 Partners with largest Australian consumer healthcare network
28 September 2020 ResApp Partners with Diabetes Queensland for SleepCheck
21 September 2020 SleepCheck Pre-Submission Package Lodged with the US FDA
1 September 2020 Continued Use of ResAppDx at COVID-19 Respiratory Clinic
31 August 2020 Appendix 4G
31 August 2020 Corporate Governance Statement
31 August 2020 Appendix 4E and Annual Report
4 August 2020 SleepCheck Now Available in 36 Countries
29 July 2020 Quarterly Activities Report and Appendix 4C
24 July 2020 Quarterly Results and Investor Conference Call Notification
17 July 2020 ResApp to Present at ShareCafe Investor Webinar
2 July 2020 Change of Director's Interest Notice
1 July 2020 Section 708A Notice and Appendix 2A
1 July 2020 ResAppDx-EU to be Launched on Phenix Health Telehealth App
1 July 2020 Coviu and ResApp Health Sign Service Agreement
30 June 2020 Ilara and ResApp Announce Evaluation of ResAppDx in Africa
29 June 2020 SleepCheck App for iPhone Now Available on the App Store
29 June 2020 DARPA WASH Program Update
18 June 2020 ResApp Signs MOU to Develop Respiratory App for Consumers
16 June 2020 Phenix and ResApp Sign Software Licensing Agreement
12 June 2020 S&P DJI Announces June 2020 Quarterly Rebalance
8 June 2020 German Health-Economic Evaluation and Update on COPD Study
11 May 2020 ResApp to Present at TechKnow Invest Roadshow Webinar
11 May 2020 ResAppDx-EU in Use at COVID-19 Respiratory Clinic.
11 May 2020 Change in substantial holding
6 May 2020 Section 708A Notice and Appendix 2A
6 May 2020 ResApp Receives Final Design Files for Hardware Devices
30 April 2020 Quarterly Update and Appendix 4C
22 April 2020 Investor Presentation
6 April 2020 Initial Director's Interest Notice
6 April 2020 ResApp Appoints Dr Michael Stein as a Non-Executive Director
1 April 2020 ResApp Announces SleepCheck, a Sleep Apnoea Screening App
30 March 2020 Coviu and ResApp Complete Initial ResAppDx-EU Integration
30 March 2020 Resignation of Non-Executive Director
26 March 2020 ResApp Builds European Market Presence
24 March 2020 ResAppDx-EU to be Deployed on Phenix Health Telehealth App
11 March 2020 Investor Conference Call
11 March 2020 Update on US FDA De Novo Classification Request
11 March 2020 Direct-to-Consumer Product Update
9 March 2020 Trading Halt
28 February 2020 Appendix 4D and Half Year Financial Report
27 February 2020 Section 708A Notice and Appendix 2A
21 February 2020 Proposed issue of Securities
21 February 2020 ResApp Completes $5 Million Capital Raising
20 February 2020 TGA Approval for Adult Respiratory Disease
19 February 2020 Trading Halt
18 February 2020 Proposed issue of Securities
18 February 2020 Functional Testing of Handheld and Wearable Devices Complete
31 January 2020 Quarterly Update and Appendix 4C
20 December 2019 Change of Director's Interest Notice x 4
20 December 2019 Appendix 3B
19 December 2019 Clinical Study of COPD Screening in Indigenous Australians
12 December 2019 ResApp Receives $1.8 Million R&D Tax Incentive Cash Rebate
28 November 2019 Results of Annual General Meeting
28 November 2019 Annual General Meeting Presentation
28 November 2019 ResAppDx-EU to be deployed on the Coviu Telehealth Platform
25 November 2019 2019 Letter to Shareholders
15 November 2019 ResApp Grants Option to Consumer Health Division of Sanofi
30 October 2019 Quarterly Update and Appendix 4C
28 October 2019 Notice of Annual General Meeting
24 October 2019 Change of Registered Office
4 October 2019 ResApp Joins Startup Creasphere Digital Health Program
3 October 2019 Change of Principal Place of Business
2 October 2019 TGA Approval for Paediatric Respiratory Disease Diagnosis
30 September 2019 Positive Results from At-Home Sleep Apnoea Study
26 September 2019 ResAppDx-EU for Adult Respiratory Disease Receives CE Mark
16 September 2019 Investor Presentation September 2019
28 August 2019 Appendix 4G
28 August 2019 Corporate Governance Statement
28 August 2019 Appendix 4E and Annual Report
23 August 2019 ResApp Receives CE Mark for ResAppDx-EU
29 July 2019 Quarterly Update and Appendix 4C
4 July 2019 Appendix 3B and Section 708A Notice
1 July 2019 At-Home Obstructive Sleep Apnoea Study Update
19 June 2019 Extension of CEO and Managing Director's Contract
13 June 2019 Investor Presentation June 2019
12 June 2019 ResApp Receives $1.785 Million R&D Tax Incentive Cash Rebate
6 June 2019 Paediatric Study Published In Peer-Reviewed Journal
5 June 2019 Appendix 3B
5 June 2019 Healthcare Leaders Appointed to Industry Advisory Board
30 May 2019 Market Clarification Announcement
29 May 2019 Customised Hardware and Wearable Devices to Expand ResApp’s Addressable Markets
6 May 2019 Appendix 3B
30 April 2019 Quarterly Update and Appendix 4C
23 April 2019 Positive Results from Australian Adult Clinical Study
15 April 2019 ResApp Submits De Novo Application to the FDA
29 March 2019 Update on Australian Adult Study and FDA De Novo Submission
19 March 2019 TechKnow Invest Roadshow Presentation
18 March 2019 Updated Top-line Results from SMARTCOUGH-C-2 Study
13 March 2019 ResApp Receives R&D Advanced Overseas Finding
28 February 2019 Appendix 4D and Half Year Financial Report
25 February 2019 Appendix 3B
11 February 2019 Appendix 3B
4 February 2019 ResApp to Host Investor Q&A Conference Call
29 January 2019 Quarterly Update and Appendix 4C
2 January 2019 ResApp Submits CE Mark Technical File
15 November 2018 Results of Annual General Meeting
15 November 2018 2018 Letter to Shareholders
14 November 2018 ResApp Clears Major Milestone for CE and TGA with ISO 13485
5 November 2018 ResApp Receives Notice of Allowance for Core Patent in Japan
31 October 2018 Appendix 4C - Quarterly
31 October 2018 CEO's Prepared Statement for Investor Conference Call
30 October 2018 ResApp Presentation at TechKnow Invest Roadshow
30 October 2018 Investor Conference Call
30 October 2018 Positive Preliminary Results from SMARTCOUGH-C-2 Study
29 October 2018 Voluntary Suspension Update
24 October 2018 Voluntary Suspension
22 October 2018 Trading Halt
17 October 2018 Response to ASX Price Query
15 October 2018 Notice of Annual General Meeting 2018
11 October 2018 Positive Results for Prospective Sleep Apnoea Clinical Study
2 October 2018 Recruitment Completed in Prospective Sleep Apnoea Study
28 September 2018 Appendix 4G
28 September 2018 Corporate Governance Statement 2018
28 September 2018 Annual Report 2018
27 September 2018 Change in substantial holding
27 September 2018 ResApp Provides Update on SMARTCOUGH-C-2 Study Timing
24 September 2018 Appendix 3B & Section 708A Notice
19 September 2018 ResApp Successfully Completes $7.5 Million Capital Raising
12 September 2018 Company Update Presentation
3 September 2018 Positive Results for Australian Prospective Paediatric Study
31 August 2018 Trading Halt
31 August 2018 Appendix 4E – Preliminary Final Report
16 August 2018 ResApp Partners with Lockheed Martin for DARPA Research
15 August 2018 Notice of Acceptance Received for Core Patent in Australia
9 August 2018 Broker Meets Biotech Presentation
2 August 2018 Enrolment Completed in Australian Paediatric Clinical Study
1 August 2018 ResApp Completes Enrolment of Smartcough-C-2 Study
31 July 2018 Quarterly Update and Appendix 4C
12 July 2018 ResApp Provides Obstructive Sleep Apnoea Study Update
28 June 2018 ResApp Provides Update on Australian Clinical Study
6 June 2018 ResApp Receives Notice of Allowance for Core Patent in US
31 May 2018 ResApp Provides SMARTCOUGH-C-2 Study Update
30 April 2018 Quarterly Update and Appendix 4C
27 April 2018 Corporate Governance Statement
26 April 2018 ResApp Receives R&D Tax Incentive Cash Rebate for FY17
24 April 2018 ResApp Signs LOI with German Private Hospital Network
16 April 2018 Response to ASX Aware Letter
12 April 2018 Investor Conference Call
10 April 2018 Investor Presentation
10 April 2018 Response to ASX Price Query
10 April 2018 ResApp Develops Obstructive Sleep Apnoea Screening Test
9 April 2018 Trading Halt
9 March 2018 ResApp Provides SMARTCOUGH-C-2 Study Update
9 March 2018 S&P DJ Indices Announces March Quarterly Rebalance
28 February 2018 Appendix 4D and Half Year Financial Report
23 February 2018 Response to ASX Price Query
31 January 2018 Appendix 4C - Quarterly Dec 2017
11 January 2018 SMARTCOUGH-C-2 Receives Third IRB Approval
8 January 2018 ResApp Enrols First Patient in SMARTCOUGH-C-2 Study
29 December 2017 Final Director's Interest Notice
29 December 2017 Initial Director's Interest Notice
29 December 2017 ResApp Appoints Non-Executive Director
19 December 2017 ResApp Receives IRB Approval at Massachusetts General
18 December 2017 Appendix 3B
18 December 2017 Positive Results from Australian Adult Clinical Studies
13 December 2017 ResApp Receives IRB Approval at Texas Children's Hospital
3 November 2017 Results of Annual General Meeting
3 November 2017 AGM CEO and Managing Director's Address to Shareholders
16 October 2017 Appendix 4C - Quarterly Sep 2017
10 October 2017 ResApp to Present at Upcoming Investor Conferences
6 October 2017 Change of Director's Interest Notice
3 October 2017 Notice of Annual General Meeting
29 September 2017 Letter to Shareholders
29 September 2017 Appendix 4G
29 September 2017 Annual Report 2017
22 September 2017 Becoming a substantial holder
20 September 2017 Updated Corporate Governance Policies
14 September 2017 Update on Field Evaluation by Medecins Sans Frontieres
12 September 2017 Investor Presentation
4 September 2017 SMARTCOUGH-C Study and Paediatric Clinical Strategy Update
31 August 2017 Appendix 4E - Preliminary Final Report
23 August 2017 Dr Philip Currie Joins ResApp's Scientific Advisory Board
21 August 2017 ResApp Receives R&D Tax Incentive Cash Refund for FY16
11 August 2017 Change of Director's Interest Notice
9 August 2017 Investor Conference Call
9 August 2017 Reinstatement to Official Quotation
9 August 2017 Preliminary Top-line Results from SMARTCOUGH-C Study
2 August 2017 Voluntary Suspension
31 July 2017 Trading Halt
22 July 2017 Appendix 3B
20 July 2017 Appendix 4C - Quarterly Jun 2017
14 July 2017 Appendix 3B
11 July 2017 Investor Presentation
10 July 2017 Morgans Initiates Research Coverage
30 June 2017 Release of Restricted Securities
22 June 2017 ResApp Provides Updated Australian Paediatric Study Results
22 June 2017 Change in substantial holding
19 June 2017 Completion of Enrolment in SMARTCOUGH-C Study
30 May 2017 ResApp Presentation at ASX Spotlight Investor Conference
30 May 2017 ResApp Provides SMARTCOUGH-C May Study Update
9 May 2017 ResAppDx to be Formally Evaluated by Doctors Without Borders
8 May 2017 Trading Halt
2 May 2017 Extension of CEO and Managing Director's Contract
2 May 2017 Appendix 3B
28 April 2017 ResApp Licenses Additional Pneumonia Diagnostic Tool from UniQuest
28 April 2017 Appendix 4C - Quarterly Mar 2017
23 April 2017 LNK: Change of Perth Address for Shareholder Purposes
19 April 2017 ResApp Extends SMARTCOUGH-C Study
28 March 2017 Change in substantial holding
21 March 2017 ResApp to Present at Upcoming Conferences in March
15 March 2017 ResApp Provides SMARTCOUGH-C Study Update
13 March 2017 Appendix 3B
10 March 2017 S&P DJ Indices Announces March Quarterly Rebalance
1 March 2017 Half Year Report - Note Disclosure Correction
28 February 2017 Appendix 4D and Half Year Accounts
23 February 2017 Change in substantial holding
21 February 2017 ResApp Presentation at the ASX CEO Sessions
14 February 2017 Appendix 3B
30 January 2017 Appendix 4C - Quarterly Dec 2016
10 January 2017 ResApp Announces Expanded Research Collaboration with MGH
16 December 2016 Change of Director's Interest Notice
16 December 2016 Appendix 3B & Section 708A Notice
9 December 2016 ResApp Initiates SMARTCOUGH-C Study in the US
28 November 2016 ResApp to Present at Wilsons Healthcare IT Conference
16 November 2016 Patersons Securities Initiates Research Coverage
16 November 2016 ResApp Receives IRB Approval at Texas Children's Hospital
11 November 2016 Change of Director's Interest Notice x 4
11 November 2016 Appendix 3B
11 November 2016 ResApp Receives IRB Approval at Massachusetts General
9 November 2016 Confirmation of Change of Auditor
2 November 2016 Results of Annual General Meeting
2 November 2016 2016 Letter to Shareholders
28 October 2016 Appendix 4C - Quarterly Sep 2016
27 October 2016 Appendix 3B & Section 708A Notice
25 October 2016 RAP receives Australian Emerging Company of Year Award
21 October 2016 ResApp Receives First Institutional Review Board Approval
18 October 2016 ResApp Investor Presentation
12 October 2016 ResApp Wins Innovation Excellence Award at Tech23 2016
7 October 2016 Appendix 3B & Section 708A Notice
4 October 2016 Notice of Annual General Meeting
3 October 2016 Further Positive Results From Adult Clinical Study
29 September 2016 Trading Halt
28 September 2016 Appendix 4G
28 September 2016 Annual Report 2016
16 September 2016 Appendix 3B & Section 708A Notice
15 September 2016 ResApp Begins Evaluation with Humanitarian Organisation
9 September 2016 Change in substantial holding
31 August 2016 Appendix 4E - Preliminary Final Report
19 August 2016 ResApp Wins Global Grand Finals at Talent Unleashed Awards
18 August 2016 ResApp Expands into Management of Respiratory Disease
4 August 2016 Change of Auditor
29 July 2016 Appendix 4C - Quarterly Jun 2016
29 July 2016 Bioshares Biotech Summit Presentation
22 July 2016 Section 708A Notice
22 July 2016 Appendix 3B
22 July 2016 ResApp Wins Category at the 2016 Talent Unleashed Awards
20 July 2016 Massachusetts General Hospital for US Clinical Study Site
20 July 2016 Becoming a substantial holder
15 July 2016 Appendix 3B
7 July 2016 Ceasing to be a substantial holder
7 July 2016 Appendix 3B
7 July 2016 Response to ASX Price and Volume Query
30 June 2016 Update on US Clinical Study
28 June 2016 Appendix 3B
21 June 2016 Positive Preliminary Results from Adult Clinical Study
20 June 2016 Trading Halt
10 June 2016 Release of Restricted Securities
10 June 2016 Appendix 3B
7 June 2016 ResApp Provides Australian Adult Study Enrolment Update
2 June 2016 Appendix 3B - Exercise of Options
2 June 2016 Appendix 3B - Release of Restricted Securities
18 May 2016 Release of Restricted Securities
18 May 2016 Appendix 3B
3 May 2016 Investor Presentation
29 April 2016 Appendix 4C - Quarterly Mar 2016
29 April 2016 Appendix 3B and Issue of Cleansing Prospectus
28 April 2016 Cleansing Prospectus
20 April 2016 ResApp Completes Oversubscribed $12.5M Capital Raising
5 April 2016 TechKnow Invest Roadshow 2016 Presentation
31 March 2016 ResApp Provides Updated Paediatric Clinical Study Results
23 March 2016 Director Resignation and Appendix 3Z
18 March 2016 Change of Director's Interest Notice
17 March 2016 Response to ASX Aware Query
15 March 2016 ResApp Presentation at the ASX CEO Sessions
14 March 2016 ResApp Completes Successful Pre-Submission Meeting with the US FDA
11 March 2016 Terms of Executive Appointment
11 March 2016 Response to ASX Price and Volume Query
7 March 2016 ResApp Collaborates with Leading Humanitarian Organisation
2 March 2016 ResApp Achieves Breakthrough Performance in Paediatric Clinical Study
1 March 2016 Appendix 4D and Half Year Accounts
26 February 2016 Second Site Added to Adult Clinical Study
24 February 2016 Initial Director's Interest Notice
22 February 2016 ResApp Appoints New Director
18 February 2016 Investor Presentation
11 February 2016 Appendix 3B
29 January 2016 Appendix 4C - Quarterly Dec 2015
27 January 2016 Change in substantial holding
22 January 2016 Appendix 3B
22 January 2016 Conversion of Options and Issue of Cleansing Prospectus
22 January 2016 Cleansing Prospectus
22 January 2016 ResApp to Exhibit at Digital Healthcare Conference in Dubai
31 December 2015 ResApp Files Pre-Submission Package with the US FDA
14 December 2015 ResApp Receives Approval to Begin Adult Study
4 December 2015 Release of Restricted Securities
30 November 2015 Results of Annual General Meeting
25 November 2015 CEO Presentation at Canary Networks Investor Roadshow
16 November 2015 Becoming a substantial holder
11 November 2015 US Roadshow - Investor Presentation
10 November 2015 Further Positive Preliminary Results from Clinical Study
4 November 2015 Exhibitor at McKinsey Global Integrated Care Conference
30 October 2015 Appendix 4C - Quarterly Sep 2015
28 October 2015 Notice of Annual General Meeting/Proxy Form
22 October 2015 Dr Abeyratne to present at Pneumonia Innovations Summit
20 October 2015 TechKnow Invest Roadshow Presentation
12 October 2015 Appendix 3Y – Change of Director’s Interest Notice
6 October 2015 Australia Biotech Invest Presentation
1 October 2015 Appendix 4G
1 October 2015 Annual Report 2015

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St,
Brisbane, QLD 4000, Australia

LEGAL
Website Terms of Use
Privacy Policy

Follow Us
  

© 2021 ResApp Health Limited. All rights reserved.